Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
NCT06702553 · View on ClinicalTrials.gov ↗
Study Summary
Cardiac surgery is a procedure that is commonly performed worldwide. Despite these technological advances, cardiac surgery remains a high-risk surgery. Among post-operative complications, acute kidney injury, respiratory failure, myocardial infarction, and stroke as well as cognitive dysfunction are significant causes of mortality in patients undergoing and following cardiac surgery. Inhaled nitric oxide (NO) therapy as a selective pulmonary vasodilator in cardiac surgery has been one of the most significant pharmacological advances in managing pulmonary hemodynamics and life threatening right ventricular dysfunction and failure. In addition, newer applications show greater promise of inhaled NO as a therapy in the area of cardiac surgery associated acute kidney injury and ischemia reperfusion. However, this remarkable expectation to inhaled NO has experienced a roller-coaster ride with high hopes and nearly universal demonstration of physiological benefits but disappointing translation of these benefits to harder clinical outcomes, like mortality. Most of our understanding on the iNO field in cardiac surgery stems from small observational or single center randomized trials, which failed to ascertain strong evidence base. As a consequence, there are only week clinical practice guidelines on the field and only European expert opinion for the use of iNO in routine and more specialized cardiac surgery. There is need for a large multicenter randomized controlled study to confirm the administration of iNO as an effective weapon for the battle against life threatening complication in high risk cardiac surgical patients. In a previous meta analysis with 27 studies included, we demonstrated that inhaled nitric oxide (NO) could reduce the duration of mechanical ventilation and reducing biomarkers of organ injury and clinical signs of organ dysfunction in cardiac surgery under cardiopulmonary bypass (CPB) , but had no significance in the ICU stay, hospital stay, and mortalit
Conditions Studied
Interventions
- DRUG Nitric Oxide Gas
- DRUG Standard Care Arm
Study Locations (3)
Massachusetts
- Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine — Boston
Shaanxi
- Xijing Hospital — Xi'an
Other
- Cardiology Research Institute, Tomsk National Research Medical Center — Tomsk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,650 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06702553
The ClinicalTrials.gov registry entry for NCT06702553 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,650 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xijing Hospital, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Cardiac Surgery appearing as the primary indexed condition, and to 2 interventions — of which Nitric Oxide Gas is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06702553 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Massachusetts, Shaanxi, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06702553 about?
NCT06702553 is a clinical study titled "Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass". Cardiac surgery is a procedure that is commonly performed worldwide. Despite these technological advances, cardiac surgery remains a high-risk surgery. Among post-operative complications, acute kidney injury, respiratory failure, myocardial infarction, and stroke as well as cognitive dysfunction are...
What is the current status of trial NCT06702553?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,650 participants. The study started on 2025-05-19. Estimated completion is 2029-03-31.
What conditions does trial NCT06702553 study?
This clinical trial studies the following conditions: Cardiac Surgery, Cardiopulmonary Bypass, Nitric Oxide, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06702553?
The interventions under investigation include: Nitric Oxide Gas (DRUG), Standard Care Arm (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06702553?
This trial is sponsored by Xijing Hospital, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06702553 being conducted?
This trial has 3 study locations across Massachusetts, Shaanxi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.